Member Info for liquid1

Consolidation is surely over!

Will it get to 20’s before a hard bounce???

COVID-19 Optical Measurement Test
In April 2020 Paraytec began work on assessing the feasibility of developing a COVID-19 test using the technology and know-how that already existed within the company. Paraytec has partnered in this work with Professor Carl Smythe and his team at the University of Sheffield to provide the proprietary microbiology aspects that are required, with the hardware and software developed by Paraytec.

Designed to give a portable test, which can generate a result in a matter of 5 to 10 minutes from a swab provided at the test location and which requires no specialist skills for its operation. It is anticipated that this product will be used in locations where the rapid screening of large numbers of people for presence of COVID-19, or any future emerging pandemic is required.

The key attributes for the testing device that we have determined are as follows:

—Simple swab or saliva sample - no clinical expertise needed
—No complex sample preparation - proprietary single-use cartridge containing analytes
—Simple portable reader - shoebox size
—No clinical training needed - automated test can be used in any location
—Rapid result - sample to result in 5 to 10 minutes, potential for further reduction
—yes/no result - option for quantification of viral load
—Platform technology - can potentially be used to detect multiple virus targets

Consolidation before rise?

19 February 2021

GSTechnologies Limited

("GST" or the "Company")

Establishment of Singapore Subsidiary

GSTechnologies Limited (LSE: GST), the integrated information and communication technology infrastructure solutions provider, is pleased to confirm that, in line with the Company's strategy, the proposed establishment of the Company's new wholly owned subsidiary in Singapore, GS Fintech PTE. Ltd. ("GS Fintech Singapore"), has now been completed to help facilitate the Company's planned expansion into blockchain related technologies and services, together with the Company's recently established UK subsidiary.

Tone Goh, Chairman of GST, commented: "As previously announced, the establishment of GS Fintech Singapore forms part of the first stage in our planned expansion into areas utilising blockchain technology following the recent appointments of Jack Bai and Shayne Tan to the Company's board and the establishment of a similar subsidiary based in the UK. I look forward to providing further updates in due course."

Braveheart Investments [LON:BRH] also had a good day, adding 21% by the close. The company has been on the radar as an investor in Remote Monitored Systems but they also own 100% of a company called Paraytec, which is involved in rapid COVID testing. Results from trials conducted by the company are expected next week and there’s growing talk from Westminster that tests like this will be fundamental to getting the economy open again. If the stars align correctly, this could be genuinely transformative for the business.

https://www.thearmchairtrader.com/premier-african-minerals-braveheart-investments-remote-monitored-systems/?amp&__twitter_impression=true

RIP

Sh*te management! FFS!

9.05am: First London cannabis-sector company climbs again

Another day, another surge in a medical cannabis stock.

MGC Pharmaceuticals Ltd (ASX:MXC) (LON:MXC) (OTCMKTS:MGCLF) has jumped 50.94% or 2.43p to 7.2p after it signed an exclusive supply and distribution agreement with Swiss PharmaCan AG, for the sale and distribution of its food supplement ArtemiC products.

The deal marks the first sales of ArtemiC as a food grade product and provides MGC Pharma direct access to the large and rapidly growing markets that are still reporting high numbers of COVID-19 cases. It follows a successful clinical trial on 50 COVID-19 patients, to evaluate the safety and efficacy of the anti-inflammatory product, ArtemiC Rescue in December 2020.

MGC was the first cannabis-sector company to float on London's main market when it joined less than two weeks ago at just 1.475p a share, although it has been listed on the Australian market since 2016.

The agreement follows the completion of a phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients, to evaluate the safety and efficacy of the anti-inflammatory product, ArtemiC™ Rescue in December 2020.

Results from the trail highlight that ArtemiC™ Rescue demonstrates the following advantages:

A full safety and efficacy profile with no drug-adverse events;
The ability to prevent deterioration of COVID-19 patients and achieve faster clinical improvement;
The ability to assist in reducing the pressure on the medical system and support coping with hospitalised patients;
The ability to reduce symptoms and pain associated with COVID-19; and
The versatility to be used in community as well as in hospitals

Watch further gains when NASDAQ start trading this afternoon!

MGC Pharmaceuticals Ltd (MGCLF) Stock Quotes | Nasdaqwww.nasdaq.com › Market Activity › Stocks
MGC Pharmaceuticals Ltd (MGCLF) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.

Market Summary > MGC Pharmaceuticals Ltd
OTCMKTS: MGCLF

Phase II double-blind trial
The agreement follows the completion of a phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients, to evaluate the safety and efficacy of the anti-inflammatory product, ArtemiC™ Rescue in December 2020.

Results from the trail highlight that ArtemiC™ Rescue demonstrates the following advantages:

A full safety and efficacy profile with no drug-adverse events;
The ability to prevent deterioration of COVID-19 patients and achieve faster clinical improvement;
The ability to assist in reducing the pressure on the medical system and support coping with hospitalised patients;
The ability to reduce symptoms and pain associated with COVID-19; and
The versatility to be used in community as well as in hospitals.

Phase II double-blind trial
The agreement follows the completion of a phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients, to evaluate the safety and efficacy of the anti-inflammatory product, ArtemiC™ Rescue in December 2020.

Results from the trail highlight that ArtemiC™ Rescue demonstrates the following advantages:

A full safety and efficacy profile with no drug-adverse events;
The ability to prevent deterioration of COVID-19 patients and achieve faster clinical improvement;
The ability to assist in reducing the pressure on the medical system and support coping with hospitalised patients;
The ability to reduce symptoms and pain associated with COVID-19; and
The versatility to be used in community as well as in hospitals.

https://www.proactiveinvestors.com.au/companies/news/941641/mgc-pharmaceuticals-signs-supply-and-distribution-agreement-with-swiss-pharmacan-for-artemic-rescue-941641.html

This agreement follows the completion of a successful phase II double-blind, placebo-controlled clinical trial on 50 COVID-19 patients across Israel and India that met all its primary and secondary endpoints.

17-Feb-21 18:01:15 40.00 4,442,312 Buy* 2m

+ 50% tomorrow or 75% possible??

Demand is high,

Capital Structure & Shareholder Information
Ordinary Shares of £0.025 each 360,229,328
The percentage in public hands is 32%

Directors Shareholdings percentage shareholding
number of Options
Avihu Tamir 27.00%
David Tsur 2.52% 2,700,000
Uzi Danino 1.02% 1,800,000
Andy Morrison 1.78% 900,000

Significant Shareholders
percentage shareholding
David Sack 4.52%

Deferred Consideration based on milestones 38,461,492.00
Employees Option – exrcise price 2.5p 1,767,284.00
Warrants – exrcise price 10p 14,700,060.00
Warrants – exrcise price 6.5p 2,701,719.00
Warrants – exrcise price 5p 1,150,000.00

https://www.kanabogroup.com/investors/

Wrong

Shares outstanding 360.23m
Free float 20.79m

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.
https://www.ft.com/content/8e279a36-8dc5-4810-b690-7394c9a501c8

Mr Tamir said the FCA had been “great” to work with and had provided clear guidance about what was needed to list in London.

The European medical cannabis market was valued at €330m in 2020, according to data provider Brightfield Group. The market for CBD, a cannabinoid that is not classified as a drug and can be sold over the counter, was valued at €1.4bn in the same year, according to Hanway Associates.

https://www.ft.com/content/8e279a36-8dc5-4810-b690-7394c9a501c8